The global facial erythema treatment market is expected to be valued at USD 299 million by 2032, up from USD 173.3 million in 2022, growing at a 5.1% CAGR during the forecast period.
The growing patient population, large pipeline drugs, and other factors are likely to drive up demand for facial erythema treatment. However, strict government regulations governing drug product approvals are expected to stymie global market growth.
On the contrary, increasing Research and Development activities and advancements in drug products are projected to provide manufacturers with more opportunities.
Clinic applications are expected to grow significantly during the forecast period due to rising practitioner awareness of early detection and efficient treatments that do not require any kind of invasive procedures or surgeries. Patients with mild cases, or those who are uncomfortable visiting healthcare facilities for treatment, are more likely to prefer at-home care.
| Attributes | Details |
|---|---|
| Facial Erythema Treatment Market Size (2022) | USD 173.3 Million |
| Facial Erythema Treatment Market Size (2032) | USD 299 Million |
| Facial Erythema Treatment Market CAGR | 5.1% |
Explore FMI!
Book a free demo
The steadily rising use of alcohol, cigarettes, and other narcotics may result in a variety of skin diseases. Furthermore, changing climatic conditions, the introduction of new products, and allergic reactions all contribute to skin abnormalities such as rosacea, which increases the use of facial erythema treatment.
The demand for minimally invasive procedures is increasing due to advantages such as shorter recovery time and less pain post-procedure. Furthermore, people are becoming increasingly aware of the various types of facial erythema treatment options available on the market. These are important factors that are expected to drive market growth.
People have a growing desire to improve their appearance, especially if they have skin conditions like perioral dermatitis, systemic illness, or rosacea. These, along with the need for skin cancer protection, are expected to significantly drive demand for facial erythema treatment.
Certain medications used during the treatment of facial erythema may cause side effects. Antibiotics, for example, can cause bloating, abdominal pain, loss of appetite, and other side effects. This factor is likely to limit the use of this type of treatment.
In contrast, due to varying utilization demands, key manufacturers are primarily focusing on new product solutions for specific applications. During the forecast period, these factors are expected to generate creative opportunities for market share and increase demand for facial erythema treatment.
North America is the most dominant facial erythema treatment market, accounting for 42% of total revenue. This is due to the majority of the population having fair skin and being prone to skin problems, resulting in the treatment's early adoption.
Climate changes, as well as population lifestyle changes, contribute to a variety of skin diseases. Furthermore, there has been an increase in skin treatment awareness in this region. These factors are likely to sustain the region's growing demand for facial erythema treatment and boost the global market growth.
The US government spends a lot of money on pharmaceuticals and medical devices every year, and they raise awareness in society. Furthermore, the business of the facial erythema treatment market is endorsed by the collaboration of multiple international companies with a slew of major hospital chains.
With revenue of 33.7%, Europe is the second-largest facial erythema treatment market. This is due to rising alcohol consumption and extensive research and development activities in the region.
Most cases of facial erythema, such as rosacea, have no known cause or treatment. It does, however, cause significant discomfort to those who suffer from these skin conditions. In many cases, it causes extreme embarrassment, anxiety, and depression. As a result, start-up companies are taking these issues into account and devising solutions to reduce their prevalence, fueling the growth of the facial erythema treatment market.
Praxis Biotechnology
Dr. Wladis and Dr. Adam founded Praxis Biotechnology in response to a lack of rosacea treatment options. Praxis Biotechnology is based at Albany Medical College. Praxis Biotechnology was recently awarded USD 50,000 after winning FuzeHub's commercialization competition. This medication, according to the non-profit, could benefit millions of people.
Legit Health
Legit Health is a Spanish start-up that offers a skin diagnostic tool. The startup's software employs artificial intelligence to classify 139 skin pathologies, with a focus on the detection of seven of these, including acne, rosacea, and dermatitis. The software's algorithms automatically fill in most medical grading systems for the seven skin conditions.
Dermatica
The team at this UK start-up develops an evidence-based treatment and delivers it monthly. The web-based platform of the start-up assists patients in developing relationships with medical professionals and seeking expert assistance when necessary. The company also develops treatments for acne, facial erythema, anti-aging, pigmentation, and melasma.
Due to the involvement of several established players, the market share for facial erythema treatment is highly competitive. These players are focusing on expanding their presence through acquisitions, expansions, product approvals, and launches in order to capitalize on market growth opportunities.
Latest Developments:
Other Market Participants of the Facial Erythema Treatment Market:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.1% from 2022 to 2032 |
| The base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD million, volume in kilotons, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments Covered | Drug Type, Disease Type, Distribution Channel, and Region. |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa, ASEAN; South Asia; Rest of Asia; Australia; and New Zealand |
| Country scope | United States of America, Canada; Mexico, Germany, United Kingdom, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | Anacor Pharmaceuticals Inc.; Astellas Pharma Inc.; Galderma S.A.; Meda Pharmaceuticals; Pfizer Inc.; Novartis International AG; Regeneron Pharmaceuticals Inc.; Sanofi S.A.; Valeant Pharmaceuticals International Inc.; Bausch Health Companies Inc.; GlaxoSmithKline plc; Merck & Co. Inc.; Enzon Pharmaceuticals; etc. |
| Customization scope | Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The facial erythema treatment market is likely to accumulate a CAGR of 5.1%, during the forecast period.
North America is the leading facial erythema treatment market with revenue of 42%.
By 2032, the facial erythema treatment market is likely to grow to a valuation of USD 299 Million.
Facial Erythema Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
